Calidi Biotherapeutics Inc. Reports Q2 2025 Financial Results and Advances in Oncology Research
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has reported its Q2 2025 financial results, showcasing a reduced net loss and significant progress in its oncology research, including FDA Fast Track Designation for its CLD-201 treatment in soft tissue sarcoma.
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company focused on developing targeted therapies for metastatic diseases, has announced its financial results for the second quarter of 2025. The company reported a net loss of $5.7 million, or $1.99 per share, an improvement from the $7.4 million, or $16.75 per share, loss recorded in the same quarter the previous year. This financial update comes alongside notable advancements in the company's research and development efforts, particularly in the field of immuno-oncology.
Research and development expenses for Q2 2025 were $2.6 million, up from $2.2 million in Q2 2024, reflecting the company's continued investment in its innovative therapies. General and administrative expenses saw a decrease to $3.1 million from $3.6 million in the prior year, indicating a more streamlined operational approach. Calidi Biotherapeutics concluded the quarter with $5.3 million in cash and $0.1 million in restricted cash, positioning it for sustained research endeavors.
Among the quarter's highlights was the release of new preclinical data on CLD-401, part of the company's proprietary RedTail platform. This data demonstrated enhanced efficacy through the systemic delivery of an IL15 superagonist and improved immune-evasion via engineered CD55 expression. Additionally, Calidi successfully raised $4.6 million through a warrant inducement offering, bringing its total gross proceeds for 2025 to $15.7 million. A significant milestone was achieved with the FDA granting Fast Track Designation for CLD-201, a treatment targeting soft tissue sarcoma, alongside the opening of an Investigational New Drug (IND) application for a Phase 1 trial.
For more detailed information on Calidi Biotherapeutics' Q2 2025 results and business highlights, visit https://ibn.fm/K3CfE. The company's progress in developing targeted therapies for metastatic diseases underscores its potential to address high unmet medical needs in oncology, marking an important step forward in cancer treatment research.